| 115.87 6.75 (6.19%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 149.78 |
1-year : | 174.94 |
| Resists | First : | 128.24 |
Second : | 149.78 |
| Pivot price | 107.24 |
|||
| Supports | First : | 106.51 |
Second : | 93.08 |
| MAs | MA(5) : | 114.02 |
MA(20) : | 107.54 |
| MA(100) : | 128.4  |
MA(250) : | 122.42 |
|
| MACD | MACD : | -2.2 |
Signal : | -4.3 |
| %K %D | K(14,3) : | 80.3 |
D(3) : | 84.5 |
| RSI | RSI(14): 52.4 |
|||
| 52-week | High : | 156 | Low : | 86.13 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TMDX ] has closed below upper band by 18.7%. Bollinger Bands are 3.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 121 - 121.57 | 121.57 - 122.11 |
| Low: | 111.92 - 112.56 | 112.56 - 113.16 |
| Close: | 114.82 - 115.83 | 115.83 - 116.77 |
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Fri, 17 Apr 2026
TransMedics Group (NASDAQ:TMDX) Stock Price Up 8.5% - Here's What Happened - MarketBeat
Thu, 16 Apr 2026
TransMedics Group Inc (TMDX) Shares Fall 6.0% -- What GF Score o - GuruFocus
Thu, 16 Apr 2026
TransMedics Group (NASDAQ:TMDX) Trading Down 5% - Here's Why - MarketBeat
Wed, 15 Apr 2026
TRANSMEDICS GROUP INC (TMDX) Fundamental Analysis & Valuation - ChartMill
Tue, 14 Apr 2026
Does TransMedics Group's (TMDX) Cash Flow Turn and Fleet Expansion Reshape Its Capital Allocation Story? - Yahoo Finance
Tue, 14 Apr 2026
TransMedics Group, Inc. $TMDX Position Lifted by Baillie Gifford & Co. - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 3.313e+007 (%) |
| Held by Institutions | 2.9 (%) |
| Shares Short | 8,230 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 4.86 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 188.1 |
| Profit Margin | 31.4 % |
| Operating Margin | 13.2 % |
| Return on Assets (ttm) | 7.2 % |
| Return on Equity (ttm) | 54.2 % |
| Qtrly Rev. Growth | 32.2 % |
| Gross Profit (p.s.) | 1.85107e+008 |
| Sales Per Share | 3.08923e+008 |
| EBITDA (p.s.) | 6.86071e+007 |
| Qtrly Earnings Growth | 1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 193 (M) |
| PE Ratio | 23.79 |
| PEG Ratio | 0 |
| Price to Book value | 0.61 |
| Price to Sales | 0 |
| Price to Cash Flow | 16.44 |
| Dividend | 0 |
| Forward Dividend | 8.33e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|